Aim To define prognostic significance of B-cell differentiation genes encoding proteins and BCL2 and BCL6 gene abnormalities in diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern.
Results Isolated BCL6 expression was more frequently found in follicular lymphoma grade 3 with >75% follicular growth pattern than in diffuse large Bcell lymphoma (P = 0.030). There were no differences in BCL2 and BCL6 gene abnormalities between diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern. Diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern patients were equally distributed in GCB and ABC groups. t(14;18)(q32;q21) was more frequently recorded in GCB group, and t(14;18)(q32;q21) with BCL2 additional signals or only BCL2 and IgH additional signals in ABC group (P = 0.004). The GCB and ABC groups showed no difference in BCL6 gene abnormalities. There was no overall survival difference between the patients with diffuse large B-cell lymphoma or follicular lymphoma grade 3 with >75% follicular growth pattern; however, GCB group had longer overall survival than ABC group (P = 0.047). Multivariate analysis showed that BCL6, CD10, and BCL2 expression, BCL2 and BCL6 abnormalities, and International Prognostic Index were not significantly related to overall survival.
Conclusion Diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern patients have very similar characteristics and their prognosis is more influenced by protein expression of B-cell differentiation stage genes than by tumor cells growth pattern, BCL2 and BCL6 abnormalities, and International Prognostic Index.
The World Health Organization (WHO) classification defines diffuse large B-cell lymphoma as a specific type of mature B-cell neoplasm (1) . However, diffuse large B-cell lymphoma types show clinical, morphological, immunophenotypic, and cytogenetic heterogeneity (2) (3) (4) (5) (6) (7) . Clinical heterogeneity of diffuse large B-cell lymphoma is a consequence of the expression of B-cell differentiation stage genes. The gene expression analysis has identified three prognostically significant molecular subtypes of diffuse large B-cell lymphoma as follows: germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 diffuse large B-cell lymphoma, which express neither genes of normal GCB-cells nor genes that are normally induced during in vitro activation of peripheral blood B-cells (8) (9) (10) .
Immunohistochemical subclassification of diffuse large B-cell lymphoma showed that GCB and ABC groups greatly differ (11) (12) (13) (14) (15) (16) (17) (18) (19) . Immunohistochemical GCB and ABC groups are not always considered to be prognostically significant predictors (16) (17) (18) (19) .
Cytogenetic analysis shows t(14;18) (q32;q21)/IgH-BCL2 to be more common in GCB than in ABC (20) (21) (22) (23) (24) .
Follicular lymphoma is the second most common non-Hodgkin B-cell lymphoma (B NHL) (1, 25) . Follicular lymphoma grade 3, in contrast to indolent follicular lymphoma grade 1 and follicular lymphoma grade 2, is clinically aggressive and has more in common with diffuse large B-cell lymphoma (5) .
The morphological subtypes of follicular lymphoma grade 3, follicular lymphoma grade 3A, and follicular lymphoma grade 3B show morphological, immunohistochemical, and cytogenetic characteristics of variable clinical importance (1) . Clinicopathologic evaluation revealed no differences in survival between follicular lymphoma grade 3A and follicular lymphoma grade 3B patients, yet follicular lymphoma grade 3 cases with a predominant diffuse component (>50%) had a significantly worse survival (25) (26) (27) . Follicular lymphoma grade 3 is characterized by variable CD10 and BCL2 protein expression and cytogenetic abnormalities, ie, rearrangements of BCL6 gene, BCL2 gene amplification, and less common t(14;18)(q32;q21) (28) . Both t(14;18)(q32;q21) and BCL2 protein expression are more common in follicular lymphoma grade 3A, while BCL6 gene rearrangements are more common in follicular lymphoma grade 3B (29) (30) (31) (32) .
Therapy and prognosis of patients with diffuse large B-cell lymphoma and follicular lymphoma are defined according to their morphological characteristics, clinical stage, and clinical prognostic factors included in the International Prognostic Index (IPI) (33, 34) .
The aim of this study was to determine whether follicular lymphoma grade 3 with >75% follicular growth pattern is part of the morphological, immunophenotypic, and cytogenetic spectrum of diffuse large B-cell lymphoma. For that purpose, we determined the following parameters: 1) protein expression of B-cell differentiation stage genes BCL6, CD10, MUM1/IRF4, CD138, and BCL2 expression in patients with diffuse large Bcell lymphoma and lymphoma grade 3; 2) subclassification into GCB and ABC groups according to the results of protein expression profile; 3) t(14;18)(q32;q21)/IgH-BCL2 and abnormalities of BCL6 gene in diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern, as well as in GCB and ABC groups; and 4) the influence of protein expression, cytogenetic abnormalities, and clinical prognostic factors of age, sex, Ann Arbor clinical stage, and IPI risk group on overall survival (35, 36) .
Patients and methods
The study included 73 patients with lymph node enlargement who were diagnosed with primary diffuse large B-cell lymphoma (n = 53) or follicular lymphoma grade 3 with >75% fol Patients were followed-up at three institutions (Merkur University Hospital, Dubrava University Hospital, and Zagreb University Hospital Center). The clinical data were available for 64 of 73 patients. The median follow-up was 19 months (1-1843 days). Data on therapy were not available for one patient. Of the remaining 63 patients, 39 received chemotherapy as first-line therapy according to the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen and 3 of these patients received additional radiotherapy (37) . Three of 63 patients received CHOP plus rituximab regimen and 4 of 63 patients received COP (cyclophosphamide, vincristine, prednisone) regimen (37) . Nine of 63 patients were initially treated with ProMACE, M-BA-COD, BACOP, or EPOCH regimens, and six of 63 patients underwent additional peripheral blood stem cell transplantation (37) . One patient died before treatment was started and one patient refused any therapy.
The study was approved by ethics committees of the Merkur University Hospital and Zagreb University School of Medicine.
Paraffin-embedded lymph node sections were analyzed with immunohistochemistry and FISH method; in cases where adequate material was available, tissue microarray was used. For tissue microarray, two representative 3-mm cores were obtained by use of biopsy needle (11G, Somatex, Teltow, Germany) and manually inserted into a paraffin block in a gird pattern.
Immunohistochemistry
Formalin-fixed, 4-µm thick paraffin sections were deparaffinized, rehydrated, and stained with antibodies to CD20 (clone L26, DAKO, Glostrup, Denmark; dilution 1:200), CD3 (polyclonal, DAKO; dilution 1:50), BCL6 (clone P1F6, Novocastra, Newcastle, UK; dilution 1:20), CD10 (clone 56C6, Novocastra; dilution 1:20), MUM1/IRF4 (polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1:100), CD138 (clone 5F7, Novocastra; dilution 1:50), and BCL2 (clone 124, DAKO; dilution 1:10). Heat-induced antigen retrieval by pressure cooking treatment PASCAL (DAKO) was performed for CD10, BCL6, MUM1/IRF4, and CD138 in 1 mmol EDTA solution, pH 8.0, at 125˚C for 30 seconds, and for BCL2 in microwave oven in Target Retrieval solution, pH 6.0, (DAKO) at 95˚C for 15 minutes. The EnVision method (DAKO) was used for immunostaining according to the manufacturer's instructions. Sections were stained in an autostainer (DAKO) and counterstained with hematoxy-lin. Cases were considered positive if 30% of tumor cells were stained with an antibody.
Patients were clustered into GCB and ABC groups according to the immunophenotypic profile criteria described by Hans et al (11) . Cases were assigned to GCB group if CD10 or both CD10 and BCL6 were positive. If CD10 and BCL6 were negative, the cases were assigned to ABC group. The cases with negative CD10 and positive BCL6 expression were classified according to MUM1/IRF4 expression: the GCB group was MUM1/IRF4 negative and the ABC group was MUM1/ IRF4 positive.
Fluorescent in situ hybridization
Tissue sections were analyzed with dual color, dual fusion translocation probe t(14;18)(q32;q21)/IgH-BCL2 (Vysis Inc., Downers Grove, IL, USA), and dual color break-apart rearrangement probe BCL6 (Vysis Inc.) (38) .
To analyze hybridization, a total of 200 nuclei per case were scored for the presence of gene signals. A cut-off of 7% was used to define a positive case.
Statistical analysis
The χ 2 test was used to compare the differences in proportions. The t test was used to evaluate the difference in age between the patient groups. Kaplan-Meier survival analysis was performed and the curves were compared by CoxMantel U-test. Overall survival time was calculated from the date of diagnosis until the last follow-up visit or death. Alive patients were censored in the analysis. Multivariate analysis was performed with the Cox stepwise proportional hazards model. Variables considered in the analysis were BCL6, CD10, and BCL2 protein expression, IPI risk group (group 1 -IPI score 0, 1, and 2; group 2 -IPI score 3, 4, and 5), BCL2 gene abnormality groups (1 - 
Results
Patients with diffuse large B-cell lymphoma were significantly older and had higher IPI score than did patients with follicular lymphoma grade 3 with >75% follicular growth pattern (Table 1) . However, there were no differences in sex distribution and Ann Arbor clinical stage between the two patient groups. The BCL6 protein expression was more frequently found in patients with follicular lymphoma grade 3 with >75% follicular growth pattern, whereas no differences between the two patient groups were recorded in CD10, MUM1/IRF4, CD138, and BCL2 expression.
The protein expression profiles of BCL6, CD10, and MUM1/IRF4 were analyzed according to the criteria described by Hans et al (11) . In 73 patients, the following 5 patterns of protein expression were found. 
MUM1/IRF4
+ in 38 cases. The first three patterns were classified as GCB profile and the latter two patterns were present as ABC profile. The distribution of cases according to the immunophenotypic profile criteria is shown in Table 1 . The GCB profile ( Figure 1 ) was found in 10 of 53 cases and ABC profile in 43 of 53 cases of diffuse large B-cell lymphoma. The GCB profile was present in 7 of 20 cases and ABC profile (Figure 2 ) in 13 of 20 cases of follicular lymphoma grade 3 with >75% follicular growth pattern (χ 2 test, P = 0.146). There was no difference in BCL2 protein expression between the GCB and ABC groups. BCL2 protein expression was found in 10 of 17 GCB and 35 of 56 ABC cases.
Cytogenetic abnormalities of diffuse large Bcell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern cases, and GCB and ABC groups are shown in Table 2 . There was no difference in the overall survival between the patients with diffuse large B-cell lymphoma and patients with follicular lymphoma grade 3 with >75% follicular growth pattern ( Figure 5 ). Multivariate analysis included data on 59 patients with complete information for all variables. None of the variables was a significant predictor of overall survival (Wald χ 2 5 test = 8.260, P = 0.143). However, overall survival was significantly better in GCB group (Figure 6 ). Clinical characteristics analysis of the GCB and ABC patient groups yielded a significant difference only according to the Ann Arbor clinical stage at diagnosis (Table 3) . ABC patients were more often in an advanced clinical stage at diagnosis than GCB patients, without any difference according to age, sex, and IPI risk.
Discussion
Our study showed that there were no differences in protein expression between patients with diffuse large B-cell lymphoma and those with follicular lymphoma grade 3 with >75% follicular growth pattern, but there were differences in the presence of BCL6, BCL2, and BCL6 cytogenetic abnormalities. Although patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern had a significantly different IPI risk at diagnosis, they showed similar overall survival. Also, diffuse large Bcell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern were equally distributed between GCB and ABC groups. However, GCB had longer overall survival than ABC group. t(14;18)(q32;q21) was more frequently recorded in GCB group, whereas t(14;18)(q32;q21) with BCL2 additional signals or only BCL2 and IgH additional signals were more frequent in ABC group; however, no differences in BCL6 gene abnormalities were observed. Also, multivariate analysis showed that BCL6, CD10, and BCL2 expression, BCL2 and BCL6 abnormalities, and IPI were not significantly related to overall survival.
In the WHO classification, diffuse large Bcell lymphoma and follicular lymphoma grade 3 are two morphologically and clinically separate types of B NHL (1) . However, the clinical course of these two types of B NHL has very similar clinical outcomes (39). Hans et al (11) showed, by correlating subclassification according to gene expression with subclassification according to protein expression in diffuse large B-cell lymphoma, that the protein expression profile of GCB and ABC groups was significantly predictive of overall survival. However, it was not uniformly confirmed as a significant predictor (11) (12) (13) (14) (15) (16) (17) (18) (19) .
Different overall survival in GCB and ABC groups may depend on the therapy regimen. According to Nyman et al (40) , in patients treated with immunochemotherapy GCB and ABC groups seem to lose their prognostic value. In the present study, only three of 63 patients received CHOP plus rituximab therapy regimen and the prognostic significance of GCB protein expression profile could not be abolished by rituximab treatment.
CD10 and BCL6 are considered germinal center differentiation stage-specific markers. However, CD10 is characterized by decreased expression in follicular lymphoma grade 3 in contrast to indolent follicular lymphoma grade 1 and follicular lymphoma grade 2 (41) . In the present study, CD10 expression was found in only 35% of cases of follicular lymphoma grade 3 with >75% follicular growth pattern and 19% of cases of diffuse large B-cell lymphoma. Also the more common BCL6 expression in follicular lymphoma grade 3 with >75% follicular growth pattern than in diffuse large B-cell lymphoma indicates that the BCL6 protooncogene controls reactive germinal centers formation as well as formation of neoplastic follicles in FL-3 (42) .
MUM1/IRF4 expression is present in non-neoplastic lymph node in a small number of late centrocytes and mostly in postgerminative B-cells, so it is considered as postgerminal differentiation stage-specific marker (43, 44) . According to Shaffer et al (3) , the high percentage of MUM1/IRF4 protein-positive diffuse large B-cell lymphoma cases, which was found in the present study, relates neoplastic B-cells in diffuse large B-cell lymphoma to postgerminal center differentiation block. Also, a large number of MUM1/IRF4 positive follicular lymphoma grade 3 cases indicate the probable late centrocyte origin of neoplastic B-cells or oncogenic translocation at an early stage of B-cell differentiation and consequently the transformed B-cell arrest at a later stage of differentiation (3). Zu et al (45) showed that interpretation of immunohistochemistry staining and scoring of MUM1/IRF4 varied greatly, with an average of only 30-37% complete agreement among observers. Also, in the present study the number of diffuse large B-cell lymphoma cases with ABC protein expression profile was higher than the number of cases recorded in literature (3, 9, 10, 12) . Therefore, we agree with de Jong et al (46) that standardization of immunohistochemistry techniques and centralized consensus review when using immunohistochemical markers are mandatory.
Negative expression of CD138 in our follicular lymphoma grade 3 with >75% follicular growth pattern cases and very low expression in diffuse large B-cell lymphoma cases, mostly with centroblast and immunoblast morphology, confirmed CD138 as a protein specific for terminal B-cell differentiation stage. t(14;18)(q32;q21) represented an initial mechanism in the pathogenesis of GCB group, while BCL2 gene additional signals were more frequently present in ABC group. BCL2 and BCL6 gene additional signals observed in the present study could indicate either additional chromosomes 18 and 3 or gene amplification (20) . t(14;18)(q32;q21) was more frequently found in GCB group and BCL2 additional signals in ABC group (19) (20) (21) (22) (23) (24) . Our study revealed that t(14;18)(q32;q21) and BCL2 gene additional signals were not mutually exclusively present in the GCB and ABC groups.
In our study, there were no between-group differences in BCL6 gene abnormalities. Barrans et al (47) found BCL6 gene rearrangement and BCL2 expression in ABC group of patients with shorter overall survival. Bea et al (48) found additional BCL6 gene signals only in ABC group. In the present study, additional BCL6 signals were also detected in the GCB group.
In conclusion, the similarity between diffuse large B-cell lymphoma and follicular lymphoma grade 3 could be examined by tumor cells growth pattern, protein expression of Bcell differentiation stage genes, common cytogenetic abnormalities, or clinical prognostic factors. The present study analyzed, for the first time, only follicular lymphoma grade 3 with >75% follicular growth pattern to exclude the influence of diffuse growth pattern component for inferior survival in grade 3 follicular lymphoma. Also, our results showed very similar characteristics of diffuse large Bcell lymphoma and follicular lymphoma grade 3 cases and implied that protein expression of the B-cell differentiation stage genes could be a superior prognostic factor than tumor cells growth pattern, cytogenetic abnormalities of BCL2 and BCL6 genes, and clinical prognostic factors.
